India, April 24 -- Lakewood-Amedex Biotherapeutics Inc. (LABT), a clinical-stage biotech focused on antimicrobial resistance, began trading yesterday on the Nasdaq Capital Market through a direct listing. Shares opened at $8.00, marking the company's entry into U.S. public markets under the ticker LABT.
The listing supports Lakewood-Amedex's efforts to advance its Bisphosphocin platform, including lead candidate Nu-3 for infected diabetic foot ulcers. The therapy is designed to address antibiotic-resistant pathogens such as MRSA and VRE, with early studies showing promising antimicrobial activity and wound healing potential.
"We plan to initiate a Phase 2a clinical trial in iDFU shortly," stated Kelvin Cooper, Ph.D., Chief Executive Offic...